NO20070930L - Stabiliserende formuleringer - Google Patents

Stabiliserende formuleringer

Info

Publication number
NO20070930L
NO20070930L NO20070930A NO20070930A NO20070930L NO 20070930 L NO20070930 L NO 20070930L NO 20070930 A NO20070930 A NO 20070930A NO 20070930 A NO20070930 A NO 20070930A NO 20070930 L NO20070930 L NO 20070930L
Authority
NO
Norway
Prior art keywords
protein
storing
methods
relatively low
stabilizing formulations
Prior art date
Application number
NO20070930A
Other languages
English (en)
Norwegian (no)
Inventor
Li Li
Angela Kantor
Shannon B Macmillan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20070930L publication Critical patent/NO20070930L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20070930A 2004-08-13 2007-02-19 Stabiliserende formuleringer NO20070930L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60131104P 2004-08-13 2004-08-13
PCT/US2005/028861 WO2006020935A2 (en) 2004-08-13 2005-08-12 Stabilizing formulations

Publications (1)

Publication Number Publication Date
NO20070930L true NO20070930L (no) 2007-05-14

Family

ID=35908214

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070930A NO20070930L (no) 2004-08-13 2007-02-19 Stabiliserende formuleringer

Country Status (18)

Country Link
US (1) US8871201B2 (pt)
EP (1) EP1784219B1 (pt)
JP (1) JP4948407B2 (pt)
KR (1) KR20070092197A (pt)
CN (1) CN101022831A (pt)
AR (1) AR051009A1 (pt)
AU (1) AU2005272603A1 (pt)
BR (1) BRPI0514340A (pt)
CA (1) CA2575870A1 (pt)
CR (1) CR8904A (pt)
EC (1) ECSP077246A (pt)
ES (1) ES2637854T3 (pt)
IL (1) IL181265A0 (pt)
MX (1) MX2007001599A (pt)
NO (1) NO20070930L (pt)
RU (1) RU2007109062A (pt)
TW (1) TW200621282A (pt)
WO (1) WO2006020935A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
JP2009534390A (ja) * 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
MX2008013508A (es) * 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
US20080070230A1 (en) * 2006-06-12 2008-03-20 Wyeth Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions
EP1950225A1 (de) * 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
CA2681752A1 (en) * 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
TWI543768B (zh) * 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2011026948A1 (en) 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
MX2011011772A (es) * 2009-05-04 2012-02-08 Abbott Biotech Ltd Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
CN113244374A (zh) * 2011-07-01 2021-08-13 生物基因Ma公司 无精氨酸的tnfr:fc-融合多肽组合物及使用方法
EP2785406A4 (en) 2011-11-30 2015-10-21 3M Innovative Properties Co MICRONADEL DEVICE WITH A PEPTIDE THERAPEUTIC AND AN AMINO ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9844594B2 (en) * 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
CN105828841A (zh) 2013-11-04 2016-08-03 辉瑞大药厂 抗-efna4抗体-药物缀合物
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
AU2015292822B2 (en) * 2014-07-21 2021-11-25 Unchained Labs Determination of protein aggregation from the concentration dependence of delta G
JP7019422B2 (ja) 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
DK3500856T3 (da) 2016-08-18 2020-12-14 Regeneron Pharma Assay til bestemmelse af et proteins potentiale for at selvassociere ved hjælp af koncentrationsafhængig selvinteraktionsnanopartikelspektroskopi
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
KR102707399B1 (ko) 2017-01-05 2024-09-13 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
CN113348163B (zh) 2019-02-12 2024-10-08 雷迪厄斯制药公司 方法和化合物
EP4142792A4 (en) * 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
US20240059768A1 (en) * 2021-01-14 2024-02-22 Hanall Biopharma Co., Ltd. A stable ophthalmic composition comprising tanfanercept, which is free of stabilizer or substantially free of stabilizer
CN115541895B (zh) * 2022-11-29 2023-05-19 天津德祥生物技术股份有限公司 一种提高微流控反定检测卡灵敏度的配方液及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3176517D1 (en) * 1980-04-24 1987-12-17 Beecham Group Plc Beta-lactam compounds, their preparation and use
GB8518416D0 (en) 1985-07-22 1985-08-29 Beecham Group Plc Compounds
US5869053A (en) * 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP1717248A1 (en) * 1997-06-04 2006-11-02 Oxford Biomedica (UK) Limited Tumor targeted vector
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
US8632778B2 (en) * 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AU2003201824A1 (en) * 2002-01-03 2003-07-24 Smithkline Beecham Corporation Methods for preparing immunoconjugates
SI2371392T1 (sl) * 2002-05-02 2015-10-30 Wyeth Holdings Llc Konjugati derivat-nosilec kaliheamicina
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CA2535804A1 (en) * 2003-08-14 2005-03-03 Wyeth Anti-lewis y anti-idiotypic antibodies and uses thereof
PE20100251A1 (es) * 2004-09-10 2010-04-10 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina

Also Published As

Publication number Publication date
MX2007001599A (es) 2007-04-10
JP2008515775A (ja) 2008-05-15
CN101022831A (zh) 2007-08-22
ES2637854T3 (es) 2017-10-17
WO2006020935A2 (en) 2006-02-23
TW200621282A (en) 2006-07-01
BRPI0514340A (pt) 2008-06-10
ECSP077246A (es) 2007-05-30
CA2575870A1 (en) 2006-02-23
EP1784219A2 (en) 2007-05-16
KR20070092197A (ko) 2007-09-12
EP1784219B1 (en) 2017-05-17
JP4948407B2 (ja) 2012-06-06
EP1784219A4 (en) 2010-02-17
US8871201B2 (en) 2014-10-28
AU2005272603A1 (en) 2006-02-23
AR051009A1 (es) 2006-12-13
RU2007109062A (ru) 2008-09-20
IL181265A0 (en) 2007-07-04
CR8904A (es) 2007-08-28
US20060115472A1 (en) 2006-06-01
WO2006020935A3 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
NO20070930L (no) Stabiliserende formuleringer
Simpson Stabilization of proteins for storage
Cuin et al. Amino acids regulate salinity-induced potassium efflux in barley root epidermis
JP2008515775A5 (pt)
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
NO20085131L (no) Lyofiliserte preparater av anti-EGFR-antistoffer
Clifford et al. Crustacean zooplankton release copious amounts of dissolved organic matter as taurine in the ocean
CH688194A5 (fr) Composition stabilisée de troponine pour immunoessais et procédé de stabilisation de troponine pour immunoessais.
Hou et al. Analysis of glutathione in biological samples by HPLC involving pre-column derivatization with o-phthalaldehyde
Chang et al. Cl− uptake mechanism in freshwater-adapted tilapia (Oreochromis mossambicus)
Cui et al. Comparative transcriptomic analysis reveals mechanisms of divergence in osmotic regulation of the turbot Scophthalmus maximus
Cleal et al. Modification of fetal plasma amino acid composition by placental amino acid exchangers in vitro
Garçon et al. Osmotic and ionic regulation, and kinetic characteristics of a posterior gill (Na+, K+)-ATPase from the blue crab Callinectes danae on acclimation to salinity challenge
JP2014501526A5 (pt)
EA200501789A1 (ru) Стабильный водный раствор эритропоэтина человека, не содержащий сывороточного альбумина
Leong et al. Na+/K+-ATPase activity during early development and growth of an Antarctic sea urchin
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
Niedźwiecka et al. NAD-preferring malic enzyme: localization, regulation and its potential role in herring (Clupea harengus) sperm cells
EP3178927B1 (en) Protein-stabilizing agent and protein-stabilizing method
Groot et al. Modelling the quantitative effect of oxygen on the ageing of primed celery seeds
Negrellos et al. Sulfinamide formation from the reaction of bacillithiol and nitroxyl
Mutyam et al. Dynamic regulation of aquaglyceroporin expression in erythrocyte cultures from cold‐and warm‐acclimated Cope's gray treefrog, Hyla chrysoscelis
ES2321373T3 (es) Procedimiento para la estabilizacion de proteinas en mezclas complejas durante su almacenamiento en disolventes acuosos.
CN110868854A (zh) 保存溶液
Walsh et al. Nitrogen metabolism and excretion in Allenbatrachus grunniens (L): effects of variable salinity, confinement, high pH and ammonia loading

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application